RxISK

Making Medicines Safer for All of Us

Drug Search by Year (Detail)

Side effect search by year (detail)

Drug:

Reaction: MALIGNANT NEOPLASM PROGRESSION

20250101 - 20251231

No. 1 - 100

Next page: 2 next page>>
No.
safetyreportid
occurcountry
patientonsetage
patientsex 1:M 2:F
Adverse reaction
Drug (openfda.generic_name, medicinalproduct)
1
25138973
JP
 46 2
Death, Malignant neoplasm progression,
LENVATINIB, PEMBROLIZUMAB,
2
25138988
JP
 2
Malignant neoplasm progression,
LENVATINIB, PEMBROLIZUMAB, PEMBROLIZUMAB,
3
25139211
CA
Gastrointestinal disorder, Metastases to bone, Malignant neoplasm progression, Breast cancer metastatic, Metastases to pelvis, Skin burning sensation, Skin fragility, Herpes zoster, Deep vein thrombosis, Menstruation irregular, Pain,
GOSERELIN, GOSERELIN, LETROZOLE, LETROZOLE TABLETS, LETROZOLE, LETROZOLE TABLETS, RIBOCICLIB,
4
25139250
GR
Malignant neoplasm progression, Hypophosphataemia,
TEBENTAFUSP,
5
25139441
IL
 2
Malignant neoplasm progression,
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB,
6
25139671
CA
 79 2
Blood glucose abnormal, Drug intolerance, Hormone receptor positive HER2 negative breast cancer, Malignant neoplasm progression, Hepatic enzyme increased,
FULVESTRANT, ALPELISIB, ALPELISIB,
7
25140224
DE
 79 2
Malignant neoplasm progression,
ENFORTUMAB VEDOTIN, METHOTREXATE, METHOTREXATE SODIUM, DOXORUBICIN HYDROCHLORIDE,
8
25140426
FR
 69 2
Malignant neoplasm progression, Neutropenia, Diarrhoea, Visual impairment, Hypertension, Oedema peripheral, Oedema,
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PEMETREXED, PEMETREXED DISODIUM, CARBOPLATIN, SELPERCATINIB, CABOZANTINIB, OSIMERTINIB, OSIMERTINIB, TRAMETINIB,
9
25140570
IL
 75 1
Hepatitis, Malignant neoplasm progression,
ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, PEMBROLIZUMAB,
10
25140624
TH
 1
Malignant neoplasm progression,
PEMBROLIZUMAB,
11
25140785
PL
 59 2
Breast cancer, Metastases to bone, Malignant neoplasm progression, Respiratory rate increased, Ventricular extrasystoles,
FULVESTRANT, RIBOCICLIB,
12
25140865
JP
 60 2
Death, Diarrhoea, Malignant neoplasm progression,
LENVATINIB, PEMBROLIZUMAB,
13
25141162
US
 1
Malignant neoplasm progression,
ENZALUTAMIDE,
14
25141226
CN
 51 1
Cerebral atrophy, Neurotoxicity, Lung neoplasm malignant, Malignant neoplasm progression, Metastases to bone, Lipids increased, Personality change,
LORLATINIB,
15
25141239
CN
 59 2
Myelosuppression, Metastases to central nervous system, Acute myeloid leukaemia, Malignant neoplasm progression, Lacunar infarction,
CYTARABINE, VENETOCLAX, VENETOCLAX, VENETOCLAX,
16
25141241
FI
 82 1
Malignant neoplasm progression, Skin reaction, Pruritus, General physical health deterioration,
ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, PEMBROLIZUMAB,
17
25141377
JP
 59 2
Malignant neoplasm progression, Breast cancer female, Ascites, Pleural effusion, Platelet count decreased, Nausea, Malaise, White blood cell count decreased, Haemoglobin decreased, Dry skin, Product dose omission in error,
TALAZOPARIB,
18
25141762
JP
 75 2
Tumour lysis syndrome, Hepatic enzyme increased, Malignant neoplasm progression,
PEMBROLIZUMAB, GEMCITABINE HYDROCHLORIDE, CISPLATIN,
19
25141885
JP
 59 2
Polyarthritis, Psoriatic arthropathy, Malignant neoplasm progression, Joint swelling, Hypertension, Palmar-plantar erythrodysaesthesia syndrome, Arthritis,
PEMBROLIZUMAB,
20
25142209
US
Malignant neoplasm progression,
LORLATINIB, CAPMATINIB,
21
25142234
JP
 8 2
Malignant neoplasm progression, Pyrexia, Hepatic function abnormal, Malaise,
PEMBROLIZUMAB, LENVATINIB, LENVATINIB,
22
25142722
JP
 52 1
Malignant neoplasm progression,
PEMBROLIZUMAB, FLUOROURACIL, CISPLATIN,
23
25142755
DE
 30 2
Superior vena cava syndrome, Malignant neoplasm progression, Pericardial effusion, Pharyngeal oedema, Pleural effusion, Atelectasis,
LISOCABTAGENE MARALEUCEL, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, FLUDARABINE PHOSPHATE,
24
25138404
DO
 2
Breast cancer metastatic, Malignant neoplasm progression, General physical health deterioration,
RIBOCICLIB, RIBOCICLIB,
25
25132239
FR
Malignant neoplasm progression, Febrile neutropenia, Fatigue,
BEVACIZUMAB, ATEZOLIZUMAB, PACLITAXEL, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM,
26
25132280
JP
 77 1
Malignant neoplasm progression, Cytokine release syndrome,
IPILIMUMAB, NIVOLUMAB,
27
25132473
CA
 52 2
Ovarian cancer, Malignant neoplasm progression,
CARBOPLATIN, DOXORUBICIN, LETROZOLE, LETROZOLE TABLETS, PACLITAXEL, TOPOTECAN, APIXABAN,
28
25132669
JP
Non-small cell lung cancer, Malignant neoplasm progression,
CAPMATINIB, CAPMATINIB,
29
25132842
JP
 74 1
Malignant neoplasm progression, Device related infection,
ZOLBETUXIMAB, FLUOROURACIL, LEVOLEUCOVORIN INJECTION, LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN, OXALIPLATIN,
30
25132911
US
 22 1
Malignant neoplasm progression, Drug ineffective for unapproved indication,
DOXORUBICIN, IFOSFAMIDE, PAZOPANIB, PAZOPANIB HYDROCHLORIDE,
31
25132978
US
 79 2
Malignant neoplasm progression, Off label use,
LENALIDOMIDE,
32
25133004
US
 66 2
Malignant neoplasm progression,
ABEMACICLIB,
33
25133420
US
 74 1
Malignant neoplasm progression,
NIVOLUMAB, IPILIMUMAB,
34
25133703
JP
 8 2
Cerebral infarction, Malignant neoplasm progression, Hypothyroidism, Hypertension, Malaise,
PEMBROLIZUMAB,
35
25133794
JP
 61 2
Coronavirus pneumonia, Malignant neoplasm progression,
PEMBROLIZUMAB, CARBOPLATIN, PACLITAXEL,
36
25134023
JP
 8 1
Malignant neoplasm progression, General physical health deterioration,
ZOLBETUXIMAB,
37
25134533
US
 39 2
Malignant neoplasm progression,
ABEMACICLIB, ANASTROZOLE, ANASTROZOLE TABLETS,
38
25134749
US
 39
Malignant neoplasm progression, Drug ineffective, Depressed mood,
FULVESTRANT, FULVESTRANT, OLAPARIB,
39
25135035
US
 57 1
Malignant neoplasm progression,
BRENTUXIMAB VEDOTIN,
40
25135278
TW
 37 2
Endometrial cancer recurrent, Therapy partial responder, Proton radiation therapy, Chemotherapy, Malignant neoplasm progression,
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, LENVATINIB, LENVATINIB, LENVATINIB, LENVATINIB,
41
25135504
PL
Chronic kidney disease, Toxicity to various agents, Metastases to lung, Hyperaesthesia, Decreased appetite, Anaemia, Polyneuropathy in malignant disease, Metastases to bone, Product use in unapproved indication, Drug dependence, Constipation, Quality of life decreased, Confusional state, Dermatitis allergic, Drug ineffective, Polyneuropathy, Allodynia, Confusional state, Decreased appetite, Malignant neoplasm progression, Neuropathy peripheral, Pain, Prostate cancer,
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, LEUPROLIDE, LEUPROLIDE, PREGABALIN, PREGABALIN, FENTANYL, FENTANYL, FENTANYL, FENTANYL, FENTANYL, MORPHINE SULFATE, DOCETAXEL, DOCETAXEL ANHYDROUS, KETOPROFEN, KETOPROFEN, GABAPENTIN, GABAPENTIN, GABAPENTIN, GABAPENTIN, DENOSUMAB, BICALUTAMIDE, MORPHINE, MORPHINE, MORPHINE, ERGOCALCIFEROL, IRON, ABIRATERONE ACETATE, ABIRATERONE, BICALUTAMIDE, GABAPENTIN, GABAPENTIN, DENOSUMAB, KETOPROFEN, DICLOFENAC, DICLOFENAC SODIUM,
42
25135531
US
 58 2
Malignant neoplasm progression,
PALBOCICLIB,
43
25135546
CO
 79
Cardio-respiratory arrest, Peripheral swelling, Malignant neoplasm progression,
ACALABRUTINIB,
44
25135719
JP
 6
Malignant neoplasm progression,
PEMBROLIZUMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN,
45
25135749
LB
 59 2
Immune system disorder, Malignant neoplasm progression, Breast cancer, Metastases to central nervous system, Metastases to bone, Metastases to liver,
PALBOCICLIB,
46
25135844
PL
 60
Neutropenia, Malignant neoplasm oligoprogression, Rectal cancer, HER2 negative breast cancer, Malignant neoplasm progression, Metastases to bone, Pulmonary mass, Osteolysis,
FULVESTRANT, FULVESTRANT, RIBOCICLIB,
47
25136109
JP
 67 1
Malignant neoplasm progression, Immune-mediated lung disease, Immune-mediated hepatic disorder,
PEMBROLIZUMAB,
48
25136132
AU
 1
Malignant neoplasm progression,
DAROLUTAMIDE,
49
25136224
US
 2
Malignant neoplasm progression, Drug ineffective,
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE,
50
25136349
CH
Blood loss anaemia, Anaemia postoperative, Adrenal insufficiency, Malignant neoplasm progression, Lymphadenopathy mediastinal, Pancreatitis, Hilar lymphadenopathy, Coeliac disease, Ophthalmic herpes zoster, Product use issue, Sarcoid-like reaction,
PEMBROLIZUMAB, LENVATINIB,
51
25136400
GB
 71 1
COVID-19 pneumonia, Malignant neoplasm progression, Pneumonitis, Pulmonary embolism,
PEMBROLIZUMAB, FUROSEMIDE, EPLERENONE, DIGOXIN, BISOPROLOL FUMARATE,
52
25136501
JP
 45 2
Death, Malignant neoplasm progression, Cerebral infarction, Meningitis,
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB,
53
25136519
FR
 68 1
Malignant neoplasm progression, Plasma cell myeloma, Immune effector cell-associated neurotoxicity syndrome, COVID-19,
ELRANATAMAB-BCMM, ELRANATAMAB-BCMM,
54
25136525
ES
 75 1
Interstitial lung disease, Interstitial lung disease, Condition aggravated, Transitional cell carcinoma metastatic, Malignant neoplasm progression, Metastases to lung,
PACLITAXEL,
55
25136530
PL
 45
Anaphylactic shock, Leukopenia, Neutropenia, Thrombocytopenia, Acetabulum fracture, Follicular lymphoma, Malignant neoplasm progression, Splenomegaly, Condition aggravated,
CARBOPLATIN, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, METHYLPREDNISOLONE, RITUXIMAB, VINCRISTINE SULFATE, VINCRISTINE SULFATE, CYTARABINE, MOSUNETUZUMAB, MOSUNETUZUMAB, MOSUNETUZUMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, PREDNISONE, ETOPOSIDE, ETOPOSIDE, CISPLATIN, IFOSFAMIDE, BORTEZOMIB FOR INJECTION, BORTEZOMIB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, BENDAMUSTINE HCL, LENALIDOMIDE,
56
25136705
CA
 57 2
Dysaesthesia, Fatigue, Joint stiffness, Mouth ulceration, Muscular weakness, Neuropathy peripheral, Pruritus, Rash maculo-papular, Malignant neoplasm progression, Papillary cystadenoma lymphomatosum, Toxicity to various agents, Off label use,
PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, FOLIC ACID, FOLIC ACID, METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS,
57
25136724
CA
 64 1
Malignant neoplasm progression, Death,
TRASTUZUMAB, TRASTUZUMAB, OXALIPLATIN, OXALIPLATIN, CAPECITABINE, CAPECITABINE, PEMBROLIZUMAB, PEMBROLIZUMAB,
58
25136758
JP
 9 2
Malignant neoplasm progression, Decreased appetite, Malaise, Gastric ulcer, General physical health deterioration,
IPILIMUMAB, NIVOLUMAB,
59
25136771
US
 1
Malignant neoplasm progression,
SEMAGLUTIDE, SEMAGLUTIDE, SEMAGLUTIDE, SEMAGLUTIDE,
60
25136959
GB
 64 2
Ventricular fibrillation, Rectal haemorrhage, Lower respiratory tract infection, Cardiac arrest, Acute myocardial infarction, Malignant neoplasm progression, Off label use,
CETUXIMAB, ENCORAFENIB,
61
25136962
CN
 51 2
Liver injury, Malignant neoplasm progression,
ABEMACICLIB,
62
25126561
GB
 1
Malignant neoplasm progression, Off label use,
LENALIDOMIDE,
63
25126708
CA
 2
Off label use, Hydronephrosis, Ovarian cancer, Malignant neoplasm progression, Colon cancer,
LETROZOLE, LETROZOLE TABLETS,
64
25127265
GB
 2
Respiratory failure, Dyspnoea, Influenza, Malignant neoplasm progression, Breast cancer metastatic, Anaemia,
FULVESTRANT, RIBOCICLIB,
65
25127431
US
Gait inability, Malignant neoplasm progression, Drug ineffective,
IVOSIDENIB,
66
25127549
JP
 48 2
Pancytopenia, Malignant neoplasm progression, Hypothyroidism, Oedema peripheral, Breast pain, Hepatic function abnormal, Tumour associated fever, Alopecia, Dyspnoea, Palmar-plantar erythrodysaesthesia syndrome, Dysphonia, Diarrhoea, Myalgia,
CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, NIVOLUMAB, NIVOLUMAB, NIVOLUMAB, NIVOLUMAB, IPILIMUMAB, IPILIMUMAB, IPILIMUMAB, IPILIMUMAB,
67
25127857
DE
 84
Dementia, Metastases to bone, Malignant neoplasm progression, Metastases to pleura, General physical health deterioration,
OSIMERTINIB, OSIMERTINIB, ERLOTINIB HYDROCHLORIDE, ERLOTINIB,
68
25128154
JP
 80
Malignant neoplasm progression, Drug ineffective, Radiotherapy,
PEMBROLIZUMAB, CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM,
69
25128936
71 1
Oesophagitis, Sepsis, Pneumonia, Vascular device infection, Therapy interrupted, Malignant neoplasm progression,
CARBOPLATIN,
70
25128972
2
Drug ineffective, Pain, Malignant neoplasm progression, Therapy interrupted,
SELPERCATINIB, SELPERCATINIB, SELPERCATINIB,
71
25129032
CA
 31 1
Metastases to salivary gland, Drug ineffective for unapproved indication, Metastases to lung, Malignant neoplasm progression, Osteosarcoma recurrent,
CISPLATIN, REGORAFENIB, ETOPOSIDE, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, IFOSFAMIDE,
72
25129121
BA
 49 2
Neutropenia, Metastases to liver, Metastases to bone, Malignant neoplasm progression,
RIBOCICLIB, RIBOCICLIB, FULVESTRANT,
73
25129278
GB
Respiratory failure, Dyspnoea, Influenza, Malignant neoplasm progression, Breast cancer metastatic, Anaemia,
FULVESTRANT, FULVESTRANT, RIBOCICLIB,
74
25129405
PL
 57 1
Myocarditis, Malignant neoplasm progression,
CARBOPLATIN, CARBOPLATIN, PEMBROLIZUMAB, PEMBROLIZUMAB, PACLITAXEL, PACLITAXEL, ERGOCALCIFEROL,
75
25129658
FR
 75 2
Immune-mediated enterocolitis, Acute kidney injury, Disease recurrence, Endometrial cancer, Malignant neoplasm progression,
CARBOPLATIN, PACLITAXEL, DOSTARLIMAB,
76
25130017
FR
 24 2
Malignant neoplasm progression, Drug ineffective for unapproved indication,
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, PREDNISONE, RITUXIMAB, DOXORUBICIN, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES,
77
25130179
CH
 84
Malignant neoplasm progression, Rash, Dry mouth, Product use issue,
PEMBROLIZUMAB,
78
25130816
AU
Malignant neoplasm progression,
NIRAPARIB,
79
25130823
JP
 8 1
Malignant neoplasm progression, Hypocalcaemia,
PEMBROLIZUMAB, DENOSUMAB, ENFORTUMAB VEDOTIN,
80
25131003
54 2
Malignant neoplasm progression,
QUETIAPINE,
81
25131333
AT
 40 2
Malignant neoplasm progression, Breast cancer metastatic, Drug ineffective, Fatigue, Weight decreased,
FULVESTRANT, LETROZOLE, LETROZOLE TABLETS, EVEROLIMUS, EVEROLIMUS TABLETS, CAPECITABINE, RIBOCICLIB, PALBOCICLIB, EXEMESTANE, TRASTUZUMAB, BEVACIZUMAB, BEVACIZUMAB,
82
25131590
BE
 47
Metastases to peritoneum, Malignant neoplasm progression,
ABEMACICLIB, ABEMACICLIB, FULVESTRANT, FULVESTRANT,
83
25131648
BR
 1
Malignant neoplasm progression, Pleural effusion, Empyema, Pneumonia,
PEMBROLIZUMAB, CARBOPLATIN, FLUOROURACIL, MIRTAZAPINE, KETOROLAC TROMETHAMINE, PREDNISONE, BUPRENORPHINE,
84
25121177
AU
Malignant neoplasm progression,
DOSTARLIMAB,
85
25121726
ES
 62 1
Malignant neoplasm progression, Drug ineffective,
86
25121928
JP
 79 2
Malignant neoplasm progression, Haemoptysis,
PEMBROLIZUMAB,
87
25121985
PL
 59
Breast cancer, Metastases to bone, Malignant neoplasm progression, Respiratory rate increased, Ventricular extrasystoles,
FULVESTRANT, FULVESTRANT, RIBOCICLIB,
88
25122083
JP
 52
Malignant neoplasm progression, Therapy partial responder, Neutrophil count decreased, White blood cell count decreased, Immune-mediated hypothyroidism, Recurrent cancer,
PEMBROLIZUMAB, BEVACIZUMAB, CARBOPLATIN, PACLITAXEL,
89
25122952
JP
Pneumonia aspiration, Malignant neoplasm progression,
GOSERELIN, GOSERELIN, ABIRATERONE ACETATE, ABIRATERONE,
90
25123389
US
Malignant neoplasm progression, Insurance issue,
91
25124182
PL
 73 2
Upper respiratory tract infection, Inflammatory marker increased, Pneumonia, Neutropenia, Malignant neoplasm progression, Follicular lymphoma, Chronic obstructive pulmonary disease,
RITUXIMAB, RITUXIMAB, RITUXIMAB, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, MOSUNETUZUMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, PREDNISONE, LENALIDOMIDE,
92
25124396
CN
 8 1
Philadelphia positive acute lymphocytic leukaemia, Malignant neoplasm progression, Off label use,
NILOTINIB, DASATINIB,
93
25124710
IT
 56 1
Malignant neoplasm progression, Drug ineffective for unapproved indication, Metastases to bone, General physical health deterioration,
TEMOZOLOMIDE, MITOTANE,
94
25124764
US
 83 1
Hormone-refractory prostate cancer, Metastases to bone, Malignant neoplasm progression, Drug ineffective,
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, CABAZITAXEL, CARBOPLATIN,
95
25125005
GB
 2
Respiratory failure, Dyspnoea, Influenza, Malignant neoplasm progression, Breast cancer metastatic, Anaemia,
FULVESTRANT, RIBOCICLIB,
96
25125139
JP
 8 2
Malignant neoplasm progression, Female genital tract fistula,
PEMBROLIZUMAB,
97
25125141
GB
Neoplasm malignant, Malignant neoplasm progression, Therapy partial responder,
PANITUMUMAB, OXALIPLATIN, FLUOROURACIL, CAPECITABINE, CETUXIMAB, AFLIBERCEPT, BEVACIZUMAB, NIVOLUMAB, ENCORAFENIB,
98
25125481
JP
 2
Malignant neoplasm progression, Drug ineffective,
PEMBROLIZUMAB, LENVATINIB,
99
25125555
US
 2
Malignant neoplasm progression,
TUCATINIB, TRASTUZUMAB, CAPECITABINE,
100
25125569
US
 52
Metastases to liver, Drug resistance, Acquired gene mutation, Malignant neoplasm progression, Metastases to central nervous system, Metastases to lung,
OSIMERTINIB, CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM,

disclaimer

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.

terms

https://open.fda.gov/terms/

license

https://open.fda.gov/license/

last_updated

2025-04-28

Next page: 2 next page>>